9q0b | pdb_00009q0b

CTX-M-15 WT in complex with BLIP E73W

spinqualitylabelsall models 9q0b, resolution 1.58Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 9q0b is a 2 chain structure with sequence from Escherichia coli and Streptomyces clavuligerus. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 1.58Å Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Function BLC15_ECO25 Extended-spectrum beta-lactamase (ESBL) which confers resistance to penicillins, as well as first, second, third and fourth-generation cephalosporins (PubMed:11470367, PubMed:28069651, PubMed:29941650, PubMed:34310213, PubMed:35515906, PubMed:35563620). Has cefotaxime- and ceftazidime-hydrolyzing activity (PubMed:28069651, PubMed:29941650, PubMed:35515906). Inactive against the carbapenem antibiotics, imipenem, meropenem and ertapenem (PubMed:11470367, PubMed:29941650). Publication Abstract from PubMed beta-lactamase enzymes inactivate beta-lactam antibiotics, leading to drug resistance. The beta-lactamase inhibitory protein (BLIP) is a naturally occurring inhibitor of beta-lactamases, with inhibition constants (K(i)) ranging from picomolar to micromolar values. For example, BLIP inhibits CTX-M-14 beta-lactamase with a K(i) of 330 nM while the K(i) for CTX-M-15 is 3 nM, despite CTX-M-14 and CTX-M-15 sharing 83% sequence identity. We used a genetic screen to identify a BLIP mutant, E73W, that potently inhibited CTX-M-14. Subsequent purification and testing of BLIP E73W revealed it is a potent, broad-spectrum inhibitor of class A beta-lactamases. We determined structures of BLIP E73W in complex with the CTX-M-14, CTX-M-15, and TEM-1 beta-lactamases to investigate the basis of the broad-spectrum inhibition. Previous structures of BLIP in complex with several class-A beta-lactamases revealed that beta-lactamase active site residue Tyr105 is found in an altered rotamer conformation. Also, in the case of the BLIP/CTX-M-15 complex, an altered conformation of the active site 103-106 loop is observed. In contrast, the BLIP E73W/beta-lactamase complexes did not show the altered conformations of Tyr105 or the 103-106 loop. Instead, the mutant's mechanism involves BLIP Trp73 trapping Tyr105 against the wall of the active site in a similar conformation as in the apo-enzyme. Interestingly, the E73W mutant binds the apo-enzyme conformation in all of the BLIP E73W/beta-lactamase complexes. Binding to the apo-enzyme conformation, which is expected to be highly populated in solution, as well as enhanced hydrophobic interactions of Trp73 with beta-lactamases are possible explanations for the high potency and broad-spectrum inhibition. A beta-lactamase inhibitory protein mutant displays high potency and a broad inhibition profile due to an altered binding mode with beta-lactamases.,Rivera P, Lu S, Ngango D, Sankaran B, Venkataram Prasad BV, Palzkill T J Biol Chem. 2025 Oct 22:110850. doi: 10.1016/j.jbc.2025.110850. PMID:41135675 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Proteopedia Page Contributors and Editors (what is this?)

OCA